Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$831.00 USD

831.00
342,620

+14.35 (1.76%)

Updated Nov 7, 2024 12:23 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences

by Zacks Equity Research

Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

by Zacks Equity Research

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates

by Zacks Equity Research

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study

by Zacks Equity Research

BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.

Ekta Bagri headshot

WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients

by Ekta Bagri

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

by Zacks Equity Research

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why

by Zacks Equity Research

Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.

Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More

by Zacks Equity Research

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Is Regeneron Pharmaceuticals (REGN) Stock a Suitable Value Pick?

by Zacks Equity Research

Let's see if Regeneron Pharmaceuticals, Inc. (REGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

by Zacks Equity Research

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

Gilead (GILD) Veklury Retains Activity Against Omicron Variant

by Zacks Equity Research

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use

by Zacks Equity Research

Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Vir (VIR) Announces Encouraging Data on COVID-19 Antibody

by Zacks Equity Research

Vir (VIR), Glaxo's sotrovimab retains neutralizing activity against the BA.2 subvariant of Omicron, per preclinical data.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

by Zacks Equity Research

Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.

Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More

by Zacks Equity Research

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

by Zacks Equity Research

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.

Company News for Feb 7, 2022

by Zacks Equity Research

Companies in The News Are: REGN,AON,RCL,VRTS

Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies

by Zacks Equity Research

Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibitor in patients with DME.

Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV

by Zacks Equity Research

Regeneron (REGN) Q4 earnings beat estimates and sales record strong year-over-year growth on the solid performance of REGEN-COV as well as Eylea and Dupixent.

Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth

by Zacks Equity Research

Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.